Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Artemisone - Artemis Therapeutics

Drug Profile

Artemisone - Artemis Therapeutics

Alternative Names: BAY 44-9585

Latest Information Update: 26 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer; Medicines for Malaria Venture
  • Developer Artemis Therapeutics
  • Class Antimalarials; Antivirals; Epoxy compounds; Pyrans; Small molecules; Thiamorpholines
  • Mechanism of Action Free radical stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malaria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malaria
  • Preclinical Cytomegalovirus infections

Most Recent Events

  • 26 Jun 2018 Artemis Therapeutics announces intention to submit IND for Cytomegalovirus infections (Artemis pipeline, June 2018)
  • 26 Jun 2018 Artemis Therapeutics completes a phase II trial in Malaria treatment in Germany prior to June 2018 (Artemis pipeline, June 2018)
  • 19 Jun 2018 Pharmacodynamics data from a preclinical trial in Malaria treatment released by Artemis Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top